Analysts: Regeneron Pharmaceuticals Inc (REGN.OQ)
REGN.OQ on NASDAQ Stock Exchange Global Select Market
271.42USD
12:55pm EDT
271.42USD
12:55pm EDT
Price Change (% chg)
$-6.87 (-2.47%)
$-6.87 (-2.47%)
Prev Close
$278.29
$278.29
Open
$277.64
$277.64
Day's High
$277.64
$277.64
Day's Low
$271.36
$271.36
Volume
68,696
68,696
Avg. Vol
220,530
220,530
52-wk High
$283.00
$283.00
52-wk Low
$131.50
$131.50
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | 0.98 | December | 2 Aug 2013 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 5 | 5 | 5 | 4 |
| (2) OUTPERFORM | 9 | 8 | 7 | 6 |
| (3) HOLD | 5 | 6 | 7 | 8 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.00 | 2.05 | 2.11 | 2.22 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-13 | 17 | 504.59 | 557.89 | 463.50 | 413.41 |
| Quarter Ending Dec-13 | 17 | 527.70 | 604.70 | 425.80 | 450.80 |
| Year Ending Dec-13 | 19 | 1,952.15 | 2,081.51 | 1,774.50 | 1,633.82 |
| Year Ending Dec-14 | 19 | 2,462.82 | 2,761.90 | 2,136.00 | 1,942.56 |
| Earnings (per share) | |||||
| Quarter Ending Sep-13 | 14 | 0.98 | 1.50 | 0.64 | 0.88 |
| Quarter Ending Dec-13 | 14 | 0.99 | 1.51 | 0.42 | 0.98 |
| Year Ending Dec-13 | 15 | 3.92 | 6.37 | 2.59 | 4.20 |
| Year Ending Dec-14 | 15 | 6.25 | 10.60 | 3.07 | 5.09 |
| LT Growth Rate (%) | 3 | 25.03 | 33.00 | 17.10 | 33.00 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Mar-13 | 428.25 | 439.66 | 11.41 | 2.66 |
| Quarter Ending Dec-12 | 393.56 | 414.60 | 21.04 | 5.35 |
| Quarter Ending Sep-12 | 349.17 | 427.69 | 78.52 | 22.49 |
| Quarter Ending Jun-12 | 259.36 | 304.40 | 45.04 | 17.37 |
| Quarter Ending Mar-12 | 173.08 | 231.79 | 58.71 | 33.92 |
| Earnings (per share) | ||||
| Quarter Ending Mar-13 | 0.98 | 0.90 | 0.08 | 7.98 |
| Quarter Ending Dec-12 | 1.10 | 1.22 | 0.12 | 10.98 |
| Quarter Ending Sep-12 | 0.95 | 1.72 | 0.77 | 80.92 |
| Quarter Ending Jun-12 | 0.27 | 0.70 | 0.43 | 162.76 |
| Quarter Ending Mar-12 | -0.24 | 0.16 | 0.40 | -168.00 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-13 | 504.59 | 502.83 | 502.13 | 502.13 | 413.41 |
| Quarter Ending Dec-13 | 527.70 | 526.03 | 528.60 | 528.60 | 450.80 |
| Year Ending Dec-13 | 1,952.15 | 1,947.37 | 1,948.14 | 1,948.14 | 1,633.82 |
| Year Ending Dec-14 | 2,462.82 | 2,451.96 | 2,475.83 | 2,475.83 | 1,942.56 |
| Earnings (per share) | |||||
| Quarter Ending Sep-13 | 0.98 | 0.98 | 1.04 | 1.04 | 0.88 |
| Quarter Ending Dec-13 | 0.99 | 0.99 | 1.06 | 1.06 | 0.98 |
| Quarter Ending Dec-13 | 3.92 | 3.92 | 3.87 | 3.87 | 4.20 |
| Quarter Ending Dec-14 | 6.25 | 5.70 | 6.07 | 6.07 | 5.09 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Sep-13 | 1 | 0 | 6 | 1 |
| Quarter Ending Dec-13 | 1 | 0 | 5 | 2 |
| Year Ending Dec-13 | 1 | 0 | 6 | 1 |
| Year Ending Dec-14 | 1 | 0 | 2 | 4 |
| Earnings | ||||
| Quarter Ending Sep-13 | 0 | 0 | 3 | 2 |
| Quarter Ending Dec-13 | 0 | 0 | 3 | 2 |
| Year Ending Dec-13 | 0 | 0 | 3 | 1 |
| Year Ending Dec-14 | 2 | 0 | 3 | 3 |
- UK cost agency recommends Bayer, Regeneron eye drug
- Regeneron settles all pending litigation with Roche's Genentech
- FEATURE-Fast climbing biotech Regeneron still has room to grow
- UPDATE 2-Regeneron raises Eylea sales view, shares hit all-time high
- Regeneron raises 2013 Eylea sales view, profit beats Street
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Earnings vs.
Estimates